New artificial intelligence ASX share rockets 13% on debut

Move over Appen, the new AI player in town went gangbusters on its first day as a public company.

| More on:
A medical professional uses a tablet showing a digital image of a human body.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors in at the ground level on a new artificial intelligence ASX share did pretty well for themselves on Friday.

Shares for Artrya Limited (ASX: AYA) listed on the ASX that morning and closed its first day at $1.52.

That's a handy 12.6% up from its initial public offer issue price of $1.35 per share.

What does Artrya do?

The Perth business develops technology to automate the diagnosis of coronary artery heart disease, which can lead to cardiac arrest.

According to Artrya co-founder and managing director John Barrington, internationally 9 million people die from such disease each year.

"This number is expected to increase over the next few decades, as ageing populations continue to put pressure on health systems," he said.

"This float will assist the company in pursuing further growth in the US, UK, Canada, and Europe."

A 10 November supplement to the original IPO prospectus showed that Artrya recently won a tender to be appointed as an artificial intelligence supplier for the National Health Service Shared Business Services (NHS SBS) Framework.

The deal means that Artrya is among a shortlist of pre-approved suppliers that UK public institutions, including 1,250 hospitals, can purchase from.

What's Artrya's pipeline?

Artrya's flagship software product is called Salix, which detects the presence of "vulnerable plaque" within a person's arteries in roughly 15 minutes.

According to the prospectus, such plaque may rupture and cause heart attacks.

Salix was developed as a collaboration between the University of Western Australia, the Harry Perkins Institute of Medical Research, and the Ottawa Heart Institute.

The software suite is scheduled for an "unrestricted launch" in Australia early in the new year. Overseas expansion will take place soon after that.

"We are keenly focused on product development and market entry strategies to ensure our shareholders are rewarded for their belief in an innovative Australian business," said Barrington.

Artrya chair Bernie Ridgeway said in the prospectus that coronary artery disease impacts an estimated 126 million people around the world. 

And the majority will have no warning signs before experiencing a heart attack.

"As the prevalence of CAD rises due to an ageing population, global health systems will have to deal with more CAD cases."

In November 2020, Salix was added to the Australian Register of Therapeutic Goods (ARTG) as a Class 1 medical device.

Artrya will sell the software in a subscription model.

"This model will help Artrya penetrate the global CCTA and ICA markets because healthcare providers pay no upfront costs to use Salix," Ridgeway said.

"Artrya believes the software-as-a-service model could deliver annuity revenue and profitable margins for the company."

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on IPOs

IPO written in circles with a man holding a smartphone and a laptop open.
International Stock News

The highs and lows of the Instacart $11 billion IPO

Here is a closer look at the latest company to hit the Nasdaq exchange.

Read more »

Two businessmen shake hands against a tech backdrop, indicating a company IPO or a merger between two technology stocks.

This $85 billion company is about to start trading on the Nasdaq. Here's what you need to know

Arm is set to join the ranks of other AI high-flyers on the Nasdaq tonight.

Read more »

A businessman hugs his computer and smiles.
Materials Shares

The ASX welcomed a new lithium stock today, and it's up 50%!

Investors have been getting excited about this new lithium stock today.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Redox share price drops after IPO

One of the biggest IPOs in some time has taken place on the ASX today.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Materials Shares

EverGreen Lithium share price rockets after IPO: everything you need to know

This lithium share is catching the eye after its successful IPO.

Read more »

A man sits uncomfortably at his laptop computer in an outdoor location at a table with trees in the background as he clutches the back of his neck with a wincing look on his face.

VHM share price plummets 11% following $30m IPO

The Aussie bourse welcomed a new rare earths stock today.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.

Hydrogen, lithium, rare earths, oh my! Here are 3 shares floating on the ASX in 2023

The new year is set to bring new faces to the Aussie bourse.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Materials Shares

Patriot Lithium share price jumps 120% after IPO

This lithium share is having a fantastic debut on the ASX...

Read more »